Short-term efficacy and safety of hyaluronic acid injection for plantar fasciopathy

Short-term efficacy and safety of hyaluronic acid injection for plantar fasciopathy

Article specifications

This clinical trial was published in 2018 in Journal of Knee Surg Sports Traumatol Arthrosc. (IF 2014:3.053) by Japanese specialists. The short-term efficacy, safety, and dose-response relationship of high-molecular-weight hyaluronic acid (HA) was investigated in patients with plantar fasciopathy. 168 patients with persistent pain from plantar fasciopathy for more than 12 weeks were randomly assigned to receive 2.5 mL of 1% HA (H-HA), 0.8 mL of 1% HA (L-HA), or 2.5 mL of 0.01% HA (control group) once a week for 5 weeks. The primary endpoint was improvement in visual analogue scale (VAS) score for pain from baseline to week 5.

 

Result

The administration of five injections of high-molecular-weight HA is an effective treatment with no serious adverse drug reactions and is a conservative treatment option for plantar fasciopathy. This treatment contributed to alleviation of pain in patients with plantar fasciopathy and improvement in their activities of daily living.